Qualigen therapeutics ceo michael poirier provides letter to shareholders

Carlsbad, calif., feb. 22, 2022 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation and diagnostics, today issues the following letter to shareholders:
QLGN Ratings Summary
QLGN Quant Ranking